On July 4, 2024, Zydus Lifesciences Limited, including its subsidiaries and affiliates (referred to as “Zydus”), received preliminary approval from the USFDA (US Food and Drug Administration) to market Azilsartan Medoxomil Tablets in 40 mg and 80 mg strengths (branded in the US as Edarbi® tablets). Azilsartan is an angiotensin II receptor blocker (ARB) used …


